Author response for 'Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant'

MLA

Carolina Terragna, et al. Author Response for “Inotuzumab Ozogamicin and Donor Lymphocyte Infusion Is a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplant.” Apr. 2021. EBSCOhost, https://doi.org/10.1002/hon.2886/v2/response1.

APA

Carolina Terragna, Francesco Barbato, F Bonifazi, Simona Soverini, Jacopo Nanni, Elisabetta Zappone, Sarah Parisi, Mario Arpinati, Gianluca Cristiano, Antonio Curti, Chiara Sartor, Gabriella Chirumbolo, Michele Cavo, Alida Dominietto, Valentina Robustelli, Giovanni Marconi, Cristina Papayannidis, Nicoletta Testoni, & Stefania Paolini. (2021). Author response for “Inotuzumab ozogamicin and donor lymphocyte infusion is a safe and promising combination in relapsed acute lymphoblastic leukemia after allogeneic stem cell transplant.” https://doi.org/10.1002/hon.2886/v2/response1

Chicago

Carolina Terragna, Francesco Barbato, F Bonifazi, Simona Soverini, Jacopo Nanni, Elisabetta Zappone, Sarah Parisi, et al. 2021. “Author Response for ‘Inotuzumab Ozogamicin and Donor Lymphocyte Infusion Is a Safe and Promising Combination in Relapsed Acute Lymphoblastic Leukemia after Allogeneic Stem Cell Transplant,’” April. doi:10.1002/hon.2886/v2/response1.